Proteome-wide mendelian randomization identifies causal plasma proteins in interstitial lung disease

Abstract Interstitial lung disease (ILD) has shown limited treatment advancements, with minimal exploration of circulating protein biomarkers causally linked to ILD and its subtypes beyond idiopathic pulmonary fibrosis (IPF). In this study, we aimed to identify potential drug targets and circulating...

Full description

Saved in:
Bibliographic Details
Main Authors: Kunrong Yu, Wanying Li, Wenjie Long, Yijia Li, Yanting Li, Huili Liao, Jianhong Liu
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-85338-y
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832594790443646976
author Kunrong Yu
Wanying Li
Wenjie Long
Yijia Li
Yanting Li
Huili Liao
Jianhong Liu
author_facet Kunrong Yu
Wanying Li
Wenjie Long
Yijia Li
Yanting Li
Huili Liao
Jianhong Liu
author_sort Kunrong Yu
collection DOAJ
description Abstract Interstitial lung disease (ILD) has shown limited treatment advancements, with minimal exploration of circulating protein biomarkers causally linked to ILD and its subtypes beyond idiopathic pulmonary fibrosis (IPF). In this study, we aimed to identify potential drug targets and circulating protein biomarkers for ILD and its subtypes. We utilized the most recent large-scale plasma protein quantitative trait loci (pQTL) data detected from the antibody-based method and ILD and its subtypes’ GWAS data from the updated FinnGen database for Mendelian randomization analysis. To enhance the reliability of causal associations, we conducted external validation and sensitivity analyses, including Bayesian colocalization and bidirectional Mendelian randomization analysis. Our study identified eight plasma proteins genetically associated with ILD or its subtypes. Among these, three proteins—CDH15 (Cadherin-15), LTBR (Lymphotoxin-beta receptor), and ADAM15 (A disintegrin and metalloproteinase 15)—emerged as priority biomarkers and potential therapeutic targets, demonstrating more reliable associations by passing a series of sensitivity analyses compared to the others. Based on these findings, we propose for the first time that CDH15, ADAM15, and LTBR hold promise as novel potential circulating protein biomarkers and therapeutic targets for the diagnosis and treatment of ILD, IPF, and sarcoidosis, respectively, especially ADAM15, and these findings have the potential to provide new perspectives for advancing the research on the heterogeneity of ILD.
format Article
id doaj-art-bfb00531060f419eb3c19c85453a32db
institution Kabale University
issn 2045-2322
language English
publishDate 2025-01-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-bfb00531060f419eb3c19c85453a32db2025-01-19T12:19:47ZengNature PortfolioScientific Reports2045-23222025-01-0115111310.1038/s41598-025-85338-yProteome-wide mendelian randomization identifies causal plasma proteins in interstitial lung diseaseKunrong Yu0Wanying Li1Wenjie Long2Yijia Li3Yanting Li4Huili Liao5Jianhong Liu6Guangzhou University of Chinese MedicineGuangzhou University of Chinese MedicineThe First Affiliated Hospital of Guangzhou University of Chinese MedicineGuangzhou University of Chinese MedicineGuangzhou University of Chinese MedicineThe First Affiliated Hospital of Guangzhou University of Chinese MedicineThe First Affiliated Hospital of Guangzhou University of Chinese MedicineAbstract Interstitial lung disease (ILD) has shown limited treatment advancements, with minimal exploration of circulating protein biomarkers causally linked to ILD and its subtypes beyond idiopathic pulmonary fibrosis (IPF). In this study, we aimed to identify potential drug targets and circulating protein biomarkers for ILD and its subtypes. We utilized the most recent large-scale plasma protein quantitative trait loci (pQTL) data detected from the antibody-based method and ILD and its subtypes’ GWAS data from the updated FinnGen database for Mendelian randomization analysis. To enhance the reliability of causal associations, we conducted external validation and sensitivity analyses, including Bayesian colocalization and bidirectional Mendelian randomization analysis. Our study identified eight plasma proteins genetically associated with ILD or its subtypes. Among these, three proteins—CDH15 (Cadherin-15), LTBR (Lymphotoxin-beta receptor), and ADAM15 (A disintegrin and metalloproteinase 15)—emerged as priority biomarkers and potential therapeutic targets, demonstrating more reliable associations by passing a series of sensitivity analyses compared to the others. Based on these findings, we propose for the first time that CDH15, ADAM15, and LTBR hold promise as novel potential circulating protein biomarkers and therapeutic targets for the diagnosis and treatment of ILD, IPF, and sarcoidosis, respectively, especially ADAM15, and these findings have the potential to provide new perspectives for advancing the research on the heterogeneity of ILD.https://doi.org/10.1038/s41598-025-85338-yInterstitial lung diseaseSubtypeProteinMendelian randomizationBiomarkerDrug target
spellingShingle Kunrong Yu
Wanying Li
Wenjie Long
Yijia Li
Yanting Li
Huili Liao
Jianhong Liu
Proteome-wide mendelian randomization identifies causal plasma proteins in interstitial lung disease
Scientific Reports
Interstitial lung disease
Subtype
Protein
Mendelian randomization
Biomarker
Drug target
title Proteome-wide mendelian randomization identifies causal plasma proteins in interstitial lung disease
title_full Proteome-wide mendelian randomization identifies causal plasma proteins in interstitial lung disease
title_fullStr Proteome-wide mendelian randomization identifies causal plasma proteins in interstitial lung disease
title_full_unstemmed Proteome-wide mendelian randomization identifies causal plasma proteins in interstitial lung disease
title_short Proteome-wide mendelian randomization identifies causal plasma proteins in interstitial lung disease
title_sort proteome wide mendelian randomization identifies causal plasma proteins in interstitial lung disease
topic Interstitial lung disease
Subtype
Protein
Mendelian randomization
Biomarker
Drug target
url https://doi.org/10.1038/s41598-025-85338-y
work_keys_str_mv AT kunrongyu proteomewidemendelianrandomizationidentifiescausalplasmaproteinsininterstitiallungdisease
AT wanyingli proteomewidemendelianrandomizationidentifiescausalplasmaproteinsininterstitiallungdisease
AT wenjielong proteomewidemendelianrandomizationidentifiescausalplasmaproteinsininterstitiallungdisease
AT yijiali proteomewidemendelianrandomizationidentifiescausalplasmaproteinsininterstitiallungdisease
AT yantingli proteomewidemendelianrandomizationidentifiescausalplasmaproteinsininterstitiallungdisease
AT huililiao proteomewidemendelianrandomizationidentifiescausalplasmaproteinsininterstitiallungdisease
AT jianhongliu proteomewidemendelianrandomizationidentifiescausalplasmaproteinsininterstitiallungdisease